The rapid enrollment pace and investigator enthusiasm suggest strong clinical site engagement, but the binary catalyst remains the 6- and 12-month endpoint data readout. Monitor for top-line safety and efficacy results, which will determine the path to FDA approval and commercial launch.
Price Chart
Executive Summary
Pulse Biosciences announced it has achieved its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE pivotal clinical study evaluating its nPulse Cardiac Catheter System for atrial fibrillation. Enrollment was completed three months ahead of the original 9-month timeline, with first patients treated in April 2026 across 15 clinical sites. Primary safety and effectiveness endpoints will be assessed at 6 and 12 months post-ablation, with pivotal data expected at a future medical conference.
Key Facts
- Enrollment target of 164 evaluable patients achieved in NANOPULSE-AF IDE pivotal study
- Enrollment completed 3 months ahead of original 9-month timeline
- First patients treated in April 2026 across 15 clinical sites
- Primary safety and effectiveness endpoints assessed at 6 and 12 months post-ablation
- Company plans to present pivotal data at a future medical society conference
Financial Impact
No financial figures provided; clinical milestone de-risks the nPulse Cardiac Catheter System's regulatory pathway for atrial fibrillation treatment
Risk Factors
- Primary endpoints at 6 and 12 months may not meet statistical significance
- Competing pulsed field ablation technologies from established players (e.g., Medtronic, Boston Scientific) could limit market share
- Company is pre-revenue with no approved products; reliance on capital markets for funding
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032271 |
| Exhibit: ex_1021860.htm | 0001437749-26-032271 |
| Document: 0001437749-26-032271-index-headers.html | 0001437749-26-032271 |
| Document: 0001437749-26-032271-index.html | 0001437749-26-032271 |
| Document: 0001437749-26-032271.txt | 0001437749-26-032271 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $52.66 (+13.69%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $52.66 (+7.27%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $52.66 (−4.60%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $52.66 (+53.75%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $52.66 (+116.09%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $52.66 (+110.72%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $52.66 (+105.62%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $52.66 (+176.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers